Rocket Returns: This Madhusudhan Kela and Sunil Singhania-owned smallcap stock has rallied 45% since April QIP

Shilpa Medicare, a stock held by Madhusudhan Kela and Sunil Singhania, has delivered a 45% return since its allotment to these ace investors four months ago in a qualified institutional placement (QIP). Singhania received 6 lakh shares of the drug company through the Abakkus Diversified Alpha Fund-2, while Kela’s joint venture fund, Cohesion MK Best Ideas Sub-Trust, was allotted over 8.79 lakh shares.

Cohesion MK Best Ideas Sub-Trust is a joint venture between Cohesion Investments and Madhusudan Kela.

At the end of the June quarter, Cohesion MK Best held a 2.12% stake in the company, representing 20.76 lakh shares. The BSE shareholding data does not reflect the latest holdings of the Abakkus Diversified Alpha Fund-2, suggesting that Singhania may have either exited the stock or reduced his stake below 1%.

The issue, launched between April 8 and 12, allocated 5% or more of the QIP to 11 funds, including four from ICICI Prudential Mutual Fund and two from Bandhan MF, among others.

Shares were allocated at Rs 455 each, which was a discount of Rs 22.33 per share, or 4.68%, from the floor price of Rs 477.33 per share. From the floor price, the stock has shot up by 62%.Shilpa Medicare’s shares have had an impressive run over the past year, returning 130% compared to the Nifty’s 29% gain.The stock closed at Rs 735 on the NSE on Monday, up Rs 37.20 or 5.33% from Friday’s closing price. The rise followed the company’s announcement that it has successfully completed phase-3 clinical studies of its novel product, SMLNUD07 (Nor Ursodeoxycholic Acid or NorUDCA) tablets. The company expects this product to “revolutionize” the treatment of Non-alcoholic Fatty Liver Disease (NAFLD).

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)